Abstract library

435 results for "use of resources".
#2058 On-going Evaluation of the Use of Resources and the Costs (UR/C) Associated with Controlled or Uncontrolled Carcinoid Syndrome (CS) in Patients (pts) with Neuroendocrine Tumours (NETs): RECOSY Study Design
Introduction: NET pts have high rates of mortality and morbidity, as wells as decreased health-related quality of life (HRQoL) due to CS. Though there is little research on the economic impact of CS, recent studies show that some symptoms, i.e. diarrhoea, are associated with higher healthcare expenditure and use of resources.
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Medical treatment - others, not specified
Presenting Author: Guillermo de La Cruz
#3041 Resource Use in Patients with Carcinoid Syndrome: A Retrospective Analysis Using the French Health Insurance National (SNDS) Database
Introduction: About 20% of patients (pts) with neuroendocrine tumors (NET) suffer from carcinoid syndrome (CS), mainly from ileum and lung NET. Pts with CS experience symptoms such as diarrhea, flushes and cardiac complications. The diarrhea occurs in almost all pts with CS and can be truly debilitating. Therefore, on top of the tumor, the burden of the symptoms further impairs quality of life and is associated with additional costs related to symptom management and pts follow-up.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Trials in Progress/Trials in Concept
Presenting Author: PhD Delphine Gueguen
#2863 Introduction of Dosimetry on PRRT Practice. A Useful Tool to Detect Responders and Evaluate Treatment Safety
Introduction: PRRT is a recognized salvage option for G1-G2 GEPNET. Currently, the Italian protocol (Lutathera AIFA Guidelines) consists in four fixed-dose of 177 Lu-DOTATATE. The dosimetry has recently been recognized as an important tool to guide PRRT but is not yet part of routine practice.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Case reports
Presenting Author: MD Federica Scalorbi
#728 NETworking-The First Three Years of the World NET Cancer Awareness Day Alliance
Introduction: Neuroendocrine tumors have an incidence of 3-5/100,000 per year, however, many patients are diagonosed late in their clinical course resulting in poor outcomes and early death. Raising awareness of the myriad presenting symptoms with resultant early diagnosis is a priority health care initiative for this disease. In 2010, the World NET Cancer Day Awareness (WNCAD) Alliance was formed with the primary mission to raise awareness of neuroendocrine tumors and promote November 10 as World NET Cancer Awareness Day
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: Dr John C Leyden
Authors: Leyden J, Sissons M, Goldstein G, ...
#1217 The Neuroendocrine Tumor (NET) Patient (pt) Perspective: Results from the First Global NET Pt Survey - A Collaboration Between the International Neuroendocrine Cancer Alliance (INCA) and Novartis Pharmaceuticals
Introduction: Despite a rising incidence of NETs, few studies document the NET pt experience. We present data on quality of life (QoL) and the global NET pt perspective.
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: ...none of the below
Presenting Author: Dr John Leyden
Keywords: Quality of life
#2978 Policy Barriers to Increasing Access to Radioligand Therapy for Neuroendocrine Cancers
Introduction: Radioligand therapy is a relatively new treatment approach used in a small number of neuroendocrine cancers and has been shown to improve overall survival and quality of life. Yet because it uses radioactivity, there are particular barriers to its greater integration into cancer care. As neuroendocrine cancers are rare, it is all the more urgent that these barriers be understood and overcome so that this treatment modality can become available to all patients who may benefit.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: Christine Merkel
#3012 Causes of Death Following Neuroendocrine Tumors Diagnosis: A United States Population-Based Analysis
Introduction: Neuroendocrine tumors (NET) are heterogeneous in terms of prognosis based on location, grade, and stage.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: DR Mohamad Sonbol
#48 Preliminary report of the use of everolimus in a patient with progressive medullary thyroid carcinoma
Introduction: Medullary thyroid carcinoma (MTC) accounts for about 5-10% of all thyroid cancers, and while disease localized to the thyroid can be cured by surgery, there is no effective treatment for disseminated MTC. Constitutive activation of the RET proto-oncogene is implicated in familial and a proportion of sporadic cases, and up-regulates the AKT/PI3-kinase/mTOR signal transduction pathway. Recent studies have shown that the inhibitor of mTOR, everolimus (RAD001, Novartis, Basel), can inhibit the proliferation of the TT cell line and human MTC tumor cells in vitro. Clinically, everolimus has been shown to attenuate the progression of some gastrointestinal neuroendocrine tumors, but its clinical use in MTC has not yet been evaluated.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Maralyn R Druce
#386 A Prospective Evaluation of the Effects of Chronic Proton Pump Inhibitor Use on Plasma Biomarker Levels in Humans
Introduction: Proton pump inhibitors (PPIs) are used primarily to treat gastroesophageal reflux disease. PPI-induced achlorhydria increases circulating gastrin and chromogranin A (CGA). CGA is a widely used biomarker for the diagnosis and follow-up for gut-based neuroendocrine tumors (NETs). PPI-induced increases in CGA or gastrin may falsely suggest the presence of a NET when none exists. Pancreastatin, a fragment of CGA, is also commonly used to diagnose and follow NETs.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr Eugene Woltering
#416 A Rare Case of Cushing Syndrome Caused by an Ectopic ACTH-Secreting Pancreatic Neuroendocrine Tumor in a Patient with Von Hipple-Lindau Disease
Introduction: Von Hipple-Lindau (VHL) disease is a rare autosomal dominant disorder, that causes the susceptibility to various tumors, both benign and malignant. The most frequent tumors are central nervous system haemangioblastomas, especially cerebellum and retinal haemangioblastomas, renal cell carcinoma /renal cysts and pheocromocytoma.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Andrea Lania